Literature DB >> 17308032

Insulin increases the potency of glycine at ionotropic glycine receptors.

Valerie B Caraiscos1, Robert P Bonin, J Glen Newell, Elzbieta Czerwinska, John F Macdonald, Beverley A Orser.   

Abstract

The mechanisms by which insulin modulates neuronal plasticity and pain processes remain poorly understood. Here we report that insulin rapidly increases the function of glycine receptors in murine spinal neurons and recombinant human glycine receptors expressed in human embryonic kidney cells. Whole-cell patch-clamp recordings showed that insulin reversibly enhanced current evoked by exogenous glycine and increased the amplitude of spontaneous glycinergic miniature inhibitory postsynaptic currents recorded in cultured spinal neurons. Insulin (1 microM) also shifted the glycine concentration-response plot to the left and reduced the glycine EC(50) value from 52 to 31 microM. Currents evoked by a submaximal concentration of glycine were increased to approximately 140% of control. The glycine receptor alpha subunit was sufficient for the enhancement by insulin because currents from recombinant homomeric alpha(1) receptors and heteromeric alpha(1)beta receptors were both increased. Insulin acted at the insulin receptor via pathways dependent on tyrosine kinase and phosphatidylinositol 3 kinase because the insulin effect was eliminated by the insulin receptor antagonist, hydroxy-2-naphthalenylmethylphosphonic acid trisacetoxymethyl ester, the tyrosine kinase inhibitor lavendustin A, and the phosphatidylinositol 3 kinase antagonist wortmannin. Together, these results show that insulin has a novel regulatory action on the potency of glycine for ionotropic glycine receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308032     DOI: 10.1124/mol.106.033563

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Allosteric potentiation of glycine receptor chloride currents by glutamate.

Authors:  Jun Liu; Dong Chuan Wu; Yu Tian Wang
Journal:  Nat Neurosci       Date:  2010-09-12       Impact factor: 24.884

Review 2.  Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.

Authors:  Xiaohui Pan; Shibing Tao; Nanwei Tong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-20       Impact factor: 6.055

3.  Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters.

Authors:  Corinne G Jolivalt; Corinne A Lee; Khara M Ramos; Nigel A Calcutt
Journal:  Pain       Date:  2008-08-27       Impact factor: 6.961

4.  Tranexamic acid concentrations associated with human seizures inhibit glycine receptors.

Authors:  Irene Lecker; Dian-Shi Wang; Alexander D Romaschin; Mark Peterson; C David Mazer; Beverley A Orser
Journal:  J Clin Invest       Date:  2012-11-26       Impact factor: 14.808

5.  Analysis of Whole Exome Sequencing with Cardiometabolic Traits Using Family-Based Linkage and Association in the IRAS Family Study.

Authors:  Keri L Tabb; Jacklyn N Hellwege; Nicholette D Palmer; Latchezar Dimitrov; Satria Sajuthi; Kent D Taylor; Maggie C Y Ng; Gregory A Hawkins; Yii-der Ida Chen; W Mark Brown; David McWilliams; Adrienne Williams; Carlos Lorenzo; Jill M Norris; Jirong Long; Jerome I Rotter; Joanne E Curran; John Blangero; Lynne E Wagenknecht; Carl D Langefeld; Donald W Bowden
Journal:  Ann Hum Genet       Date:  2017-01-09       Impact factor: 2.180

6.  Positive Modulation of the Glycine Receptor by Means of Glycine Receptor-Binding Aptamers.

Authors:  Nancy Dekki Shalaly; Eduardo Aneiros; Michael Blank; Johan Mueller; Eva Nyman; Michael Blind; Michael A Dabrowski; Christin V Andersson; Kristian Sandberg
Journal:  J Biomol Screen       Date:  2015-06-12

7.  Hyperpolarization-activated current (In) is reduced in hippocampal neurons from Gabra5-/- mice.

Authors:  Robert P Bonin; Agnieszka A Zurek; Jieying Yu; Douglas A Bayliss; Beverley A Orser
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.